Systemic lupus erythematosus is a chronic, systemic, autoimmune disease of unknown etiology characterized by impaired T-cell responses and dysregulation of B-cell activation that results in the production of autoantibodies,generation of circulatory immune complexes, and activation of the complement system. Objective: To investigate the presence and clinical significance of anti-Scl-70 antibodies in patients with systemic lupus erythematosus (SLE) and tocorrelate disease activity and different clinical parameters with anti-Scl-70 antibody. Methods: Fifty six patients with SLE fulfilling the ACR criteria for the diagnosis of SLE and 20 healthy controls were studied. Levels of antibodiesagainst Scl-70 were determined using enzyme-linked immunosorbent assay(ELISA). Disease activity was assessed using systemic lupus activity measure (SLAM). Results: The analysis performed indicated that the mean of serum anti-Scl-70 was significantly higher in the whole SLE patient group. There wassignificant correlation between anti-Scl-70 and renal involvement with higher frequency of renal involvement in anti-Scl-70 positive patient. The prevalence of chest involvement was significantly higher in SLE patients with anti-Scl-70. The SLAM score showed no significant correlation with anti-Scl-70. Conclusion: Anti-Scl-70 antibody might be present in the setting of SLE, without scleroderma features. These antibodies might be a marker of increased risk of pulmonary andrenal involvement.